Shreeram Aradhye, Global Drug Development & Chief Medical Officer
Shreeram Aradhye, Global Drug Development & Chief Medical Officer

Shreeram Aradhye, M.D.

President, Global Drug Development & Chief Medical Officer since May 16, 2022

Shreeram Aradhye, M.D.

President, Global Drug Development & Chief Medical Officer since May 16, 2022

Shreeram Aradhye, Global Drug Development & Chief Medical Officer

Member of the Executive Committee.

As President, Global Drug Development & Chief Medical Officer for Novartis, Shreeram Aradhye is responsible for advancing the Novartis pipeline of investigational medicines to bring transformative new treatment options to patients with serious diseases.

Shreeram’s organization leads the clinical development of potential new medicines, running large clinical trials and steering the path to regulatory approval, while also maintaining oversight of ongoing patient safety and regulatory activities for licensed therapies. With an aim to bring up to 20 major new medicines to patients by 2026 – including for cardiovascular and immunological conditions, neurological disorders and various forms of cancer – Shreeram and his team play a central role in driving the company’s long-term growth and delivering on its purpose to improve and extend people’s lives.

It’s a true privilege and great responsibility to develop and deliver the next generation of transformational medicines founded in innovative science.

Shreeram is passionate about developing investigational medicines, recognizing the hope and trust of patients participating in clinical trials. He has dedicated his professional career to improving patients’ lives, first as an academic clinician and then as a drug developer and business leader.

Shreeram took on his current role at Novartis in May 2022, rejoining the company after spending several years at US biotechnology companies, including leading the development of multiple clinical stage RNAi assets at Dicerna Pharmaceuticals. He first joined Novartis in 1999 and over the course of 20 years held a succession of leadership roles in the US, Switzerland, Germany and India, including Global Head of Medical Affairs for the Pharmaceuticals Business Unit and Development Head for the Neuroscience Franchise.

Before joining the life sciences industry, Shreeram was an attending physician and assistant professor of medicine and a transplant nephrologist at the University of Pennsylvania. He completed his medical training at the All India Institute of Medical Sciences in 1989, after which he received additional specialty training in internal medicine and nephrology in the US.

Shreeram has a keen interest in photography, leveraging the camera lens as vehicle to notice, be present and observe.

Professional experience

  • Executive Vice President & Chief Medical Officer, Dicerna Pharmaceuticals, US (Sept 2020 – Mar 2022)
  • Executive Vice President & Chief Development Officer, Axcella Health, US (May 2019 – Aug 2020)
  • Global Head, Medical Affairs and Chief Medical Officer, Pharmaceuticals, Novartis, US & Switzerland (Feb 2017 – April 2019)
  • Global Head, Development Franchise, Neuroscience, and US Head, Development, Novartis, US & Switzerland (Nov 2013 – Feb 2017)
  • Executive Global Program Head, Multiple Sclerosis, Novartis, Switzerland (Aug 2012 – Oct 2013)
  • Head, Global Development India, Novartis, India (Jun 2011 – Jul 2012)
  • Head, Global Clinical Development & Medical Affairs, Biosimilars, Sandoz, Germany (Dec 2009 – Jun 2011)
  • Joined Novartis in 1999 holding positions of increasing responsibility

Education

  • Chief Resident and Teaching Fellow in Internal Medicine, Newton Wellesley Hospital, US
  • Resident in Internal Medicine, Newton Wellesley Hospital, US
  • Fellow in Nephrology, St Luke's Roosevelt Medical Center, US
  • Resident in Internal Medicine (M.D.), All India Institute of Medical Sciences, India
  • Bachelor of Medicine and Bachelor of Surgery, All India Institute of Medical Sciences, India

Information is accurate as of May 16, 2022